News 14.07.2017 Bio-Technopark based startup Biognosys offering proteomics solutions has raised $5 million from new and existing investors in an extended series C round. The funds will be used to bring proteomics to the broader life science research market. Biognosys is a proteomics company offering innovative services and products for highly multiplexed protein...
News 07.07.2017 Zurich – The greater Zurich region has all the aces needed for a successful biotechnology centre, says Roger Nitsch, president of the Schlieren-based company Neurimmune. It has the best and the brightest – and the right infrastructure in the shape of the Bio-Technopark Schlieren-Zurich. The greater Zurich region is well on...
News 30.05.2017 Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the first patient was dosed in the phase 2 multiple myeloma study of its lead oncology asset MP0250. In the first phase 2 study, the efficacy and safety...
News 19.05.2017 Virometix today announced that it has raised CHF 5.0 million in new equity financing to support further development of its vaccine candidates for RSV and cancer immunotherapy. The investment was backed by existing shareholders and new private investors with longstanding experience in the life science sector. Virometix plans to use the new...
News 12.05.2017 Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin® therapies, today announced that the Board of Directors unanimously decided to appoint Patrick Amstutz, Ph.D., co-founder of the company, as Chief Executive Officer and to nominate him to become a member of...